Pacific Biosciences of California Inc (Pacific Biosciences) designs, develops, and manufactures sequencing systems to solve complex genetic abnormalities. The company reports its operations under a single segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The company's products and technology, including HiFi long-read sequencing technology, serve a wide range of applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology. PacBio's customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Pacific Biosciences R&D arm focuses on making significant investments in research and development. The company's R&D efforts focus on developing new and existing platforms, increasing throughput, decreasing costs for customers, innovating across end-to-end workflows to improve usability, and developing new applications for the advancement of human health. The company also innovates across end-to-end workflows to improve usability and develop new applications for the advancement of human health. In addition to platform development, it continuously innovates across end-to-end workflows to improve usability and develop new applications for the advancement of human health. As of December 31, 2025, the company owns or holds exclusive licenses to 450 issued US patents, 69 pending US patent applications, eight pending Patent Cooperation Treaty (PCT) patent applications, 318 issued foreign patents, and 104 pending foreign patent applications. The company also has non-exclusive patent licenses with various third parties. In FY2025, the company spent US$97.3 million on its R&D activities, which as a percentage of revenue stood at 60.8%. As of December 31, 2025, the company had 162 employees working in its R&D division.